ESC Congress 2026 Abstract · Oct 26, 2026
Perioperative empagliflozin and risk of acute kidney injury after cardiac surgery: a systematic review and meta-analysis
By Alves GA, Bonafe T, Souza BL et al.
Introduction: Hypertension is the leading modifiable risk factor for cardiovascular disease globally, driven by a sodium-rich, potassium-poor dietary phenotype. Whilst potassium-enriched salt substitutes (PESS) demonstrate hypotensive potential, widespread clinical implementation is hindered by theoretical concerns regarding fatal hyperkalaemia, particularly in vulnerable populations. Purpose: To evaluate the efficacy of PESS in reducing Systolic Blood Pressure (SBP) and Major Adverse Cardiovascular Events (MACE), whilst assessing safety regarding hyperkalaemia and sudden death. Methods: We conducted a systematic review following PRISMA guidelines, searching PubMed and Embase databases without date restrictions. Eligibility criteria included RCTs involving adults with hypertension or high cardiovascular risk, comparing PESS (specifically 75% NaCl / 25% KCl formulations) against regular salt. Outcomes included SBP, MACE, 24-hour urinary Na/K excretion, hyperkalaemia, and sudden death. Statistical analysis utilised RStudio with a random-effects model to account for clinical heterogeneity. Effect measures included Mean Difference (MD) and Hazard Ratio (HR) or Risk Ratio (RR) with 95% Confidence Intervals (CI) and I2 statistic for heterogeneity. Results: The search identified 104 records; following screening, four RCTs were included (N=24,998), comprising the SSaSS, DECIDE-Salt, Bernabe-Ortiz (Peru), and Barros (Brazil) trials. Efficacy analysis demonstrated robust SBP reduction, with MDs ranging from -1.29 mmHg in the Peruvian cohort to -7.10 mmHg in DECIDE (Pooled MD: -4.51 mmHg; 95% CI -6.10 to -2.92; I2=91%). Significant protection against MACE was observed with high consistency (I2<25%) in large trials (SSaSS: HR 0.86 [95% CI 0.77-0.96]; DECIDE: HR 0.60 [95% CI 0.38-0.96]). The mechanism was validated by urinary excretion changes: sodium reduction (-15.2 to -55.5 mmol/day) and potassium increase (+16.1 to +20.6 mmol/day). Regarding safety, whilst biochemical hyperkalaemia events increased significantly (RR 2.10; 95% CI 1.35-3.26; I2=0%), the meta-analysis of Sudden Death demonstrated no significant difference between groups (RR 1.05; 95% CI 0.82-1.34; I2=0%), indicating a dissociation between laboratory markers and fatal clinical endpoints. Conclusion: Replacing regular salt with potassium-enriched formulations (75/25) is an efficacious strategy for BP reduction and MACE prevention. The biochemical risk of hyperkalaemia did not translate into increased sudden mortality in large-scale trials. Future studies should focus on Western populations to address dietary heterogeneity and consolidate generalisability.Risk of AKI: Empagliflozin vs. Control.Risk of POAF: Empagliflozin vs. Control.
doi.org/10.1093/eurheartj/ehag785.4118Open accessInterventions